Your session is about to expire
← Back to Search
Vorolanib + Atezolizumab for Small Cell Lung Cancer
Study Summary
This trial will test whether adding vorolanib to atezolizumab improves how long participants are cancer-free after standard chemotherapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 1225 Patients • NCT02008227Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have untreated brain metastases or brain bleeding, and I haven't had preventive brain radiation.My high blood pressure has not been controlled with medication for over 3 weeks.I have not coughed up a significant amount of blood recently nor does my cancer invade major blood vessels.I haven't taken antibiotics in the last 2 weeks, except for prevention.I am 18 years old or older.You need to have a certain level of a type of white blood cell called neutrophils.I have not received a live flu vaccine within the last 4 weeks or during the study.I have not had severe infections or been hospitalized for them in the last 2 weeks.I do not have active tuberculosis.I agree to use birth control during and after the study and am not breastfeeding.I have active hepatitis B or had it in the past but it's resolved now.I've had 3-4 cycles of specific cancer treatment without my tumor growing and can start the study treatment within 6-8 weeks.I have not had a serious blood clot in the last 3 months.My blood clotting tests are within normal limits, or if on blood thinners, within the therapeutic range.I have an active autoimmune disease like lupus or rheumatoid arthritis.I am on a daily aspirin or similar blood thinner, but no more than 325 mg/day.Your liver enzymes (AST and ALT) are within a certain range, unless you have cancer that has spread to your liver.My blood tests for bone marrow and organ function are normal.I am on a stable dose of a non-Coumadin blood thinner.I have not had severe bleeding in my stomach or intestines in the last 3 months.I have not had a GI perforation or fistula, or risk factors for one, in the last 6 months.You have had allergic reactions to drugs similar to vorolanib or atezolizumab.I had cancer before, but I finished all treatments over 2 years ago and am now cancer-free.I am taking more than 10 mg/day of prednisone or its equivalent.I have small cell lung cancer treated only with specific initial drugs.I have not had any serious wounds, ulcers, or bone fractures in the last 28 days.I have not had major surgery in the last 28 days or minor surgery in the last 7 days.Your platelet count is at least 100,000 per microliter of blood.I haven't had a heart attack, stroke, or similar event in the last 6 months.I have a history of lung scarring or inflammation.I have a serious liver condition, such as severe hepatitis, cirrhosis, or fatty liver disease.I am fully active and can carry on all my pre-disease activities without restriction.Your hemoglobin level is at least 9.0 grams per deciliter.Your total bilirubin level should be less than 1.5 times the upper limit of normal.My urine protein levels are low enough for the trial.My kidney function is within the required range.
- Group 1: Vorolanib + Atezolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many test subjects are taking part in this research?
"That is correct. As of right now, the trial detailed on clinicaltrials.gov is recruiting patients. The listing was first made on October 7th, 2020 and was last updated June 30th, 2022. They are currently looking for 33 individuals from 1 location to participate."
Are there any negative side effects associated with Atezolizumab?
"Atezolizumab is a medication that showed some promise in earlier trials, but its efficacy has yet to be conclusively proven. Our team rates it as a 2 in terms of safety."
Does this experiment hold any groundbreaking potential?
"Atezolizumab is being studied in 356 active clinical trials across the globe. The first trial began in 2008 and, after completion of its Phase 2 stage, was approved for use with 720 patients. To date, 79 Atezolizumab studies have been completed."
For what purpose is Atezolizumab most commonly prescribed?
"Atezolizumab is an immunotherapy medication that has shown promise in the treatment of small cell lung cancer as well as neoplasms, non-small cell lung carcinoma, and postoperative patients."
Are patients still being recruited for this research project?
"This trial is currently looking for patients, according to the latest information on clinicaltrials.gov. The study was first posted on October 7th 2020, and was last updated on June 30th 2022."
Share this study with friends
Copy Link
Messenger